BIOFRONTERA INC (BFRI) Fundamental Analysis & Valuation

NASDAQ:BFRI • US09077D2099

Current stock price

0.99 USD
+0.01 (+1.03%)
Last:

This BFRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BFRI Profitability Analysis

1.1 Basic Checks

  • In the past year BFRI has reported negative net income.
  • BFRI had a negative operating cash flow in the past year.
  • In the past 5 years BFRI always reported negative net income.
  • In the past 5 years BFRI always reported negative operating cash flow.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • BFRI has a Return On Assets (-36.89%) which is comparable to the rest of the industry.
  • BFRI's Return On Equity of -100.53% is on the low side compared to the rest of the industry. BFRI is outperformed by 66.15% of its industry peers.
Industry RankSector Rank
ROA -36.89%
ROE -100.53%
ROIC N/A
ROA(3y)-63.1%
ROA(5y)-52.29%
ROE(3y)-307.05%
ROE(5y)-251.27%
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 73.71%, BFRI belongs to the top of the industry, outperforming 80.73% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BFRI has grown nicely.
  • The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.14%
GM growth 5Y7.28%
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BFRI Health Analysis

2.1 Basic Checks

  • BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BFRI has been increased compared to 1 year ago.
  • BFRI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BFRI has been reduced compared to a year ago.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • BFRI has an Altman-Z score of -5.48. This is a bad value and indicates that BFRI is not financially healthy and even has some risk of bankruptcy.
  • BFRI has a worse Altman-Z score (-5.48) than 65.63% of its industry peers.
  • A Debt/Equity ratio of 0.44 indicates that BFRI is not too dependend on debt financing.
  • The Debt to Equity ratio of BFRI (0.44) is worse than 60.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -5.48
ROIC/WACCN/A
WACC7.83%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.52 indicates that BFRI should not have too much problems paying its short term obligations.
  • BFRI's Current ratio of 1.52 is on the low side compared to the rest of the industry. BFRI is outperformed by 73.44% of its industry peers.
  • A Quick Ratio of 1.40 indicates that BFRI should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.40, BFRI is doing worse than 67.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.4
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BFRI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 71.71% over the past year.
  • Looking at the last year, BFRI shows a quite strong growth in Revenue. The Revenue has grown by 11.75% in the last year.
  • Measured over the past years, BFRI shows a quite strong growth in Revenue. The Revenue has been growing by 17.21% on average per year.
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%293.2%
Revenue 1Y (TTM)11.75%
Revenue growth 3Y13.31%
Revenue growth 5Y17.21%
Sales Q2Q%36.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.65% on average over the next years. This is a very strong growth
  • BFRI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.49% yearly.
EPS Next Y92.63%
EPS Next 2Y45.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.75%
Revenue Next 2Y15.86%
Revenue Next 3Y15.85%
Revenue Next 5Y18.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. BFRI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • BFRI's earnings are expected to grow with 45.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.65%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BFRI Dividend Analysis

5.1 Amount

  • BFRI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BFRI Fundamentals: All Metrics, Ratios and Statistics

BIOFRONTERA INC

NASDAQ:BFRI (4/6/2026, 5:26:01 PM)

0.99

+0.01 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-13
Inst Owners17.2%
Inst Owner Change0%
Ins Owners4.7%
Ins Owner Change21.28%
Market Cap11.53M
Revenue(TTM)41.71M
Net Income(TTM)-10.54M
Analysts82.5
Price Target6.12 (518.18%)
Short Float %1.89%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)69.02%
Min EPS beat(2)-4.8%
Max EPS beat(2)142.84%
EPS beat(4)1
Avg EPS beat(4)-2.33%
Min EPS beat(4)-114.32%
Max EPS beat(4)142.84%
EPS beat(8)2
Avg EPS beat(8)-119.06%
EPS beat(12)2
Avg EPS beat(12)-92.96%
EPS beat(16)4
Avg EPS beat(16)-62.64%
Revenue beat(2)1
Avg Revenue beat(2)0.85%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)3.83%
Revenue beat(4)2
Avg Revenue beat(4)-2.96%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)6.66%
Revenue beat(8)2
Avg Revenue beat(8)-9.21%
Revenue beat(12)3
Avg Revenue beat(12)-7.82%
Revenue beat(16)3
Avg Revenue beat(16)-6.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)36.11%
EPS NQ rev (3m)36.11%
EPS NY rev (1m)0%
EPS NY rev (3m)34.62%
Revenue NQ rev (1m)12.64%
Revenue NQ rev (3m)12.64%
Revenue NY rev (1m)3.41%
Revenue NY rev (3m)4.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS3.58
BVpS0.9
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.89%
ROE -100.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.71%
FCFM N/A
ROA(3y)-63.1%
ROA(5y)-52.29%
ROE(3y)-307.05%
ROE(5y)-251.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.14%
GM growth 5Y7.28%
F-Score3
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.45%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 1.4
Altman-Z -5.48
F-Score3
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)5.56%
Cap/Depr(5y)5.25%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%293.2%
EPS Next Y92.63%
EPS Next 2Y45.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.75%
Revenue growth 3Y13.31%
Revenue growth 5Y17.21%
Sales Q2Q%36.16%
Revenue Next Year14.75%
Revenue Next 2Y15.86%
Revenue Next 3Y15.85%
Revenue Next 5Y18.49%
EBIT growth 1Y34.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIOFRONTERA INC / BFRI Fundamental Analysis FAQ

What is the fundamental rating for BFRI stock?

ChartMill assigns a fundamental rating of 2 / 10 to BFRI.


What is the valuation status for BFRI stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOFRONTERA INC (BFRI). This can be considered as Overvalued.


How profitable is BIOFRONTERA INC (BFRI) stock?

BIOFRONTERA INC (BFRI) has a profitability rating of 2 / 10.